Chae-Ok Yun's Biography

Chae-Ok Yun, Professor, Department of Bioengineering, Hanyang University

Chae-Ok Yun is currently a Professor of Bioengineering at Hanyang University, Seoul, Korea. She is also an Adjunct Professor of Pharmaceuticals and Pharmaceutical Chemistry at University of Utah, United States, an Affiliate Professor of Medicine at University of Washington, United States, a Guest Professor of Sichuan University, China, and an Adjunct Professor of Genomics at Yonsei University, Korea. She has served as Deputy Editor of Molecular Therapy (2010-), Associate Editor of BMC Cancer (2010-) and Cancer Gene Therapy (2013-), Editorial Board member of Journal of Controlled Release (2010-), Gene Therapy and Regulation (2010-), International Journal of Cancer Research & Diagnosis (2013-), Regenerative Therapy (2016-), and Advanced Drug Delivery Review (2016-), an Associate Editor in Chief of Oncolytic Virotherapy (2017-), and an Editorial Advisor of BMC Biomedical Engineering. She is also a Member of The National Academy of Engineering of Korea. She was awarded the Excellence in Research Award from American Society of Gene Therapy in 2002 and Excellent Professor in Research Achievement from Yonsei University in 2003, 2005, 2007, 2008, and 2011. She received the Bowon Award for Best Research Activity from Yonsei University in 2007. She also was awarded the Excellence in Research Award from Korean Society of Gene Therapy (2011, 2012, and 2014), Korean Government Ministry award from Ministry of Science (2013), LG Yonam Foundation (2016), and International Society of Cancer Gene Therapy (2016). Her research interests include cancer gene therapy, immunotherapy, angiogenesis, combination of viral vectors and non-viral vectors, nanomedicine, and tumor biology. One of her gene therapeutics is in clinical trial against cancer patients.

Optimizing the Delivery of Anticancer Immune Response-Inducing Oncolytic Adenovirus and Adjuvant Immunotherapeutic

Monday, 11 November 2019 at 10:20

Add to Calendar ▼2019-11-11 10:20:002019-11-11 11:20:00Europe/LondonOptimizing the Delivery of Anticancer Immune Response-Inducing Oncolytic Adenovirus and Adjuvant ImmunotherapeuticCell and Gene Therapy Asia 2019 in Kobe, JapanKobe, JapanSELECTBIOenquiries@selectbiosciences.com

Currently, intratumoral injection of an oncolytic adenovirus (Ad) remains the conventional administration route in clinical trials. Nonetheless, the locally administered Ad disseminates to the surrounding nontarget tissues and has short biological activity due to immunogenicity of Ad, which inadvertently promotes rapid clearance and insufficient intratumoral retainment of therapeutics. To this end, we developed biocompatible and biodegradable hydrogels to enhance the therapeutic efficacy of oncolytic Ads via single intratumoral administration. A hydrogel-based intratumoral delivery of oncolytic Ads led to prolonged viral retainment within tumor tissues and restricted nonspecific shedding to normal tissues (up to 161.4-fold higher retainment than naked oncolytic Ad). Notably, hydrogel systems attenuated oncolytic Ad-mediated antiviral immune response, which can cause adverse inflammatory response, while preserving the viruses’ ability to induce robust antitumor immune response. One of the hydrogel was capable of efficiently co-delivering and protecting both therapeutic dendritic cells and oncolytic Ad in tumor tissues, thus potentiating the robust antitumor immune response by combination therapy regimen. Collectively, hydrogel-based delivery system enables biological activity of both immunotherapeutic agents could be preserved over a considerable time period in immunosuppressive and hostile tumor microenvironment that significantly diminishes the efficacy of immunotherapeutics. A delivery system, which simultaneously modulates both antiviral and antitumor immune response in a favorable manner to the potency and safety of oncolytic virotherapy in a complex immunological microenvironment of tumors, is of great importance as it may finally enable oncolytic virotherapy to reach its full potential and achieve optimal therapeutic outcome against clinical cancer.

Add to Calendar ▼2019-11-11 00:00:002019-11-12 00:00:00Europe/LondonCell and Gene Therapy Asia 2019Cell and Gene Therapy Asia 2019 in Kobe, JapanKobe, JapanSELECTBIOenquiries@selectbiosciences.com

Corporate Sponsors

	Lab-on-a-Chip, Microfluidics, & Organ-on-a-Chip Asia 2024 Location: Tokyo, Japan Date: 07/11/2024 - 08/11/2024

	Organoids and Spheroids Europe 2024 Location: Rotterdam, The Netherlands Date: 24/06/2024 - 25/06/2024

	Lab-on-a-Chip and Microfluidics World Congress 2024 Location: Laguna Hills, California Date: 18/11/2024 - 20/11/2024